RxDoctor Payments Data

Rebecca Gazze-Mcilroy, DO

Family Medicine · Dover, DENPI 1972550424

Payments from drug & device makers

$901in general payments, 2019–2025

Across 52 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$192
  • Astellas Pharma US Inc$135
  • Lilly USA, LLC$119
  • AstraZeneca$102
  • Boehringer Ingelheim$93
  • Pfizer$54
  • plus $206 from 7 others

What the payments were for

  • Food & beverage$901100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$901 in reported general payments places this provider in the 65th percentile of 352 family medicine providers in Delaware.

See all family medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$169,871
Medicare patients
395
Services billed
2,190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide138$212,310
JanuviaSitagliptin Phosphate35$52,712
FarxigaDapagliflozin Propanediol47$45,104
JardianceEmpagliflozin36$44,910
MounjaroTirzepatide29$36,787
TrulicityDulaglutide18$29,035
LinzessLinaclotide37$27,858
Xtampza ErOxycodone Myristate24$25,882
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$22,677
EliquisApixaban18$15,363
RybelsusSemaglutide12$10,919
MyrbetriqMirabegron11$9,488
Emgality PenGalcanezumab-Gnlm12$8,337
Rosuvastatin Calcium263$7,096
Tresiba Flextouch U-100Insulin Degludec12$5,384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$192$223,229150 claims
Lilly USA, LLCMounjaro, Trulicity$119$65,82247 claims
AstraZenecaFarxiga$102$45,10447 claims
Boehringer IngelheimJardiance$93$44,91036 claims
PfizerEliquis$54$15,36318 claims
Astellas Pharma US IncMyrbetriq$135$9,48811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 352 family medicine providers in Delaware.

Other family medicine in Dover

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →